<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="324">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01982578</url>
  </required_header>
  <id_info>
    <org_study_id>INC-GEN-2013-01</org_study_id>
    <secondary_id>U1111-1150-4063</secondary_id>
    <nct_id>NCT01982578</nct_id>
  </id_info>
  <brief_title>Genistein as a Possible Treatment for Alzheimer's Disease.</brief_title>
  <acronym>GENIAL</acronym>
  <official_title>Effect of Activation of the Receptor PPARg/RXR as a Possible Treatment for Alzheimer's Disease. Role of Genistein.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación para la Investigación del Hospital Clínico de Valencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Valencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación para la Investigación del Hospital Clínico de Valencia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Genistein is an isoflavone that has antioxidant and neuroprotective effects on Alzheimer's&#xD;
      disease (AD).&#xD;
&#xD;
      A few years ago our group reported that genistein increased PPARg (peroxisome proliferator&#xD;
      activated receptor gamma) levels. By the way, activation of retinoid X receptor (RXR)-PPARg&#xD;
      dimer, will make overexpressing apolipoprotein E (apoE), which mediates the degradation of&#xD;
      amyloid beta (AB). Therefore, we believe that if this phytoestrogen administration increases&#xD;
      the availability of the transcription factor, it can increase apoE, and also AB degradation.&#xD;
&#xD;
      The main aim of this study is to determinate the effect of 60 mg BID of genistein&#xD;
      administration, during 360 days, compared to placebo group, in AD patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alzheimer's disease is devastating in terms of personal wellbeing as well as for society. Any&#xD;
      effort to prevent and/or treat this disease is always sought after. Recently, an exciting new&#xD;
      possibility was opened by modulating a cellular component called RXR-PPARG. A successful&#xD;
      experimental treatment for Alzheimer's was found by activating RXR. But we previously showed&#xD;
      that a component of soya, i.e., genistein, is able to activate the other part of the&#xD;
      RXR-PPARG molecule, i.e., the PPARG moiety. Genistein, moreover, does not have the&#xD;
      undesirable effect of bexarotene and is a food component. Our preliminary results in animals&#xD;
      indicate that genistein is effective in the treatment of experimental Alzheimer's in mice.&#xD;
      Epidemiological evidence shows that individuals who live in Eastern societies who have a high&#xD;
      genistein intake (because they eat a lot of soya) have lower rates of Alzheimer's disease.&#xD;
&#xD;
      Thus we propose a controlled clinical trial to test if administration of the food component&#xD;
      genistein is able to prevent or cure, at least partially, Alzheimer's disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Amyloid beta concentration in cerebrospinal fluid (CSF)</measure>
    <time_frame>Day 0 and day 360 (plus or minus 7 day)</time_frame>
    <description>The primary study endpoint is the change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in MMSE.</measure>
    <time_frame>Day 0, day 180, day 360, (plus or minus 7 days)</time_frame>
    <description>Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in T@M (Memory Alteration Test).</measure>
    <time_frame>Day 0, day 180, day 360, (plus or minus 7 days)</time_frame>
    <description>Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.This is a memory screening test, capable for discriminating between subjects with subjective memory complaints (SMC) (without objective memory impairment) and patients with amnestic mild cognitive impairment (A-MCI) and with mild Alzheimer's disease (AD) (Archives of Gerontology and Geriatrics. 2010 Mar-Apr;50(2):171-4. doi: 10.1016/j.archger.2009.03.005. Epub 2009 Apr 16)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in TAVEC (Verbal Learning Test Spain-COmplutense).</measure>
    <time_frame>Day 0, day 180, day 360, (plus or minus 7 days)</time_frame>
    <description>Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Clock test.</measure>
    <time_frame>Day 0, day 180, day 360, (plus or minus 7 days)</time_frame>
    <description>Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Barcelona Test.</measure>
    <time_frame>Day 0, day 180, day 360, (plus or minus 7 days)</time_frame>
    <description>Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Rey Complex figure Test.</measure>
    <time_frame>Day 0, day 180, day 360, (plus or minus 7 days)</time_frame>
    <description>Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Genistein Pharmacokinetics.</measure>
    <time_frame>Day 0, day 360, (plus or minus 7 days)</time_frame>
    <description>Change from baseline to the end of the treatment,and the change between the treatment group and the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Equol Pharmacokinetics.</measure>
    <time_frame>Day 0, day 360, (plus or minus 7 days)</time_frame>
    <description>Change from baseline to the end of the treatment,and the change between the treatment group and the placebo group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Product: Genistein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg of genistein BID for 360 days. Intervention: Product: Genistein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 placebo capsule BID for 360 days. Intervention: Product: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Genistein</intervention_name>
    <description>Subjects will be randomized 1:1 to receive 360 days of double blind treatment of genistein.</description>
    <arm_group_label>Product: Genistein</arm_group_label>
    <other_name>Fisiogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>360 days of double blind treatment of placebo.</description>
    <arm_group_label>Product: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with mild cognitive impairment (MCI) compatible with prodromal AD.&#xD;
&#xD;
          -  Mini-Mental State Examinations (MMSE) score between over 24 inclusive.&#xD;
&#xD;
          -  CSF levels of AB, p-TAU compatible with AD.&#xD;
&#xD;
          -  18 years or older.&#xD;
&#xD;
          -  Must have a study partner who is able and willing to comply with all required study&#xD;
             procedures.&#xD;
&#xD;
          -  Willing and able to provide informed consent by either the subject or subject's legal&#xD;
             representative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who does not meet the inclusion criteria.&#xD;
&#xD;
          -  Thyroid abnormalities with or without treatment.&#xD;
&#xD;
          -  Immune abnormalities in blood analyses.&#xD;
&#xD;
          -  Patient suffers hormone dependent neoplasia.&#xD;
&#xD;
          -  Take a diet rich on isoflavones.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Viña, MD PhD (hon)</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Valencia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitat de València</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 30, 2013</study_first_submitted>
  <study_first_submitted_qc>November 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2013</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación para la Investigación del Hospital Clínico de Valencia</investigator_affiliation>
    <investigator_full_name>Jose Vina</investigator_full_name>
    <investigator_title>Professor M.D. Ph. D. (hon)</investigator_title>
  </responsible_party>
  <keyword>Treatment</keyword>
  <keyword>Genistein</keyword>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Cerebrospinal fluid</keyword>
  <keyword>Amyloid beta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genistein</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 3, 2022</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

